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background: The methodologies for assessment of anti-human leukocyte (anti-HLA) antibodies in heart transplantation (HT) have evolved, with 
sensitive flow cytometry largely replacing cytotoxicity techniques. The impact of these changes on post-HT outcomes, however, is uncertain. We 
sought to determine trends in pre-HT anti-HLA antibody assessment and whether the methodology of assessment identifies patients at higher risk of 
graft loss.
Methods:The United Network for Organ Sharing (UNOS) database was queried for all HTs in adults and children between June 2004 and March 
2013. Results of anti-HLA antibody assessment are recorded as a % panel reactive antibody (% PRA). Patients were considered positive (+PRA) for 
class I and/or II anti-HLA antibodies if the pre-HT % PRA was ≥ 10%. Differences in graft survival according to methodology of anti-HLA antibody 
assessment (flow cytometry vs. cytotoxicity) were evaluated, and multivariable analysis was used to identify independent risk factors for graft loss.
results: During the study period, 12,858 patients meeting inclusion criteria underwent HT. In 2005-2006, 16.8% had a +PRA; in 2010-2011, this 
increased to 23.1% (P<0.01) in conjunction with increased use of flow cytometry. Patients with +PRA by flow cytometry had worse graft survival than 
those with a negative PRA by either flow cytometry or cytotoxicity (P<0.001 for flow; P=0.002 for cytotoxicity). There was no difference in graft survival 
between patients with a +PRA by flow cytometry and those with a +PRA by cytotoxicity, nor was there a difference in graft survival for patients with a 
negative PRA by either technique. By multivariable analysis, a pre-HT +PRA by flow cytometry independently predicted graft loss (hazard ratio 1.17, 
95% CI 1.05 - 1.31).
conclusion: In HT recipients, there has been a significant increase over time in the use of flow cytometry for pre-HT assessment of anti-HLA 
antibodies, with a concomitant decrease in utilization of cytotoxicity. Patients with a pre-HT +PRA by flow cytometry had worse graft survival than 
those with a negative PRA by either technique; a pre-HT +PRA by flow cytometry predicted graft loss. Further strategies are needed to mitigate graft 
loss in these patients.
